A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer

Official Title

Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial


This I/II study will evaluate to see how safe and useful irreversible electroporation (also called NanoKnife) is in patients with locally advanced pancreatic cancer.

Trial Description

Primary Outcome:

  • Adverse event rate
  • Overall survival rate
Secondary Outcome:
  • Progression-free survival rate
  • Overall survival rate of disease
  • Progression-free survival rate of disease
In this phase 1/II trial, patients with locally advanced pancreatic ductal carcinoma will be assigned to receive interventional treatment of irreversible electroporation (IRE).

IRE will be performed by laparotomy under general anesthesia in the operating room.

All patients enrolled of the study will have a biopsy at the time of laparotomy. A baseline positron emission tomography (PET) scan using a contrast called [F-18]-Fluoroazomycin Arabinoside (FAZA) will be performed post enrolment and pre-study treatment to evaluate the levels of hypoxia in the tumour. A further scan will be performed at the first follow-up 12 weeks post completion of treatment. Blood will be collected of regular blood tests and correlative studies at baseline and during the study. Computed tomography (CT) scans will be done at baseline, 4 weeks post treatment, 12 weeks and 24 weeks follow up. Quality of Life (QOL) questionnaires will be completed at baseline and during the study. Patients will be given optional consent for biobanking of left over tissue and blood for future analysis. Patients will be followed up 4 weeks post treatment, then every 12 weeks until death.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society